Mathai Mammen, J&J EVP of pharmaceuticals, R&D (Rob Tannenbaum)
Promising to slim down and speed up, the ‘new’ J&J shakes up the executive committee ahead of the big split
The new J&J has a fresh corporate face to show the public — several in fact.
As the healthcare conglomerate follows a now familiar pharma path …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
